Q: It appears that IPOs are no longer a liquidity event for venture capital investors in biotechnology companies, given their difficulty relative to days past and the disappointing post-money valuations accorded newly public companies. What is the implication for VCs if this situation persists?
A: This correctly describes biotech IPOs during the current financing window. On average, recent IPOs raised $30-40M proceeds, less than...







